Use of AI/ML and Generative AI
for Prognosis in Myelodysplastic Syndrome Using De-identified Market Clarity Database
Myelodysplastic Syndrome (MSD) is a rare group of bone marrow failure disorders in which the body fails to make sufficient healthy blood cells. According to a study, about 20,000 new cases of MDS are diagnosed every year and an estimated 60,000 to 175,000 patients are living with MDS, in the US. Currently, with no definite cure for this disease, proper disease management helps slow the progression and ease the symptoms in patients. This study provides the evaluation of the AI/ML technique to predict MDS prognosis and staging and helps to estimate more accurate disease progression in patients. MDS stages in a patient are a crucial predictor of disease outcome and a key factor in determining the appropriateness of treatment. The accuracy of the prognostic prediction model will lead to improved clinical management of MDS patients.
Vikash Verma
Director Data Science at Optum
Experienced Healthcare Strategic Planning Professional \| Global Pharmaceutical and Healthcare Expert With over 15 years of exceptional hands-on experience in the global pharmaceutical and healthcare industry, I am a highly accomplished and sought-after professional in healthcare/Pharmaceutical strategic planning. My expertise spans diverse regions, including the US, EMAP, and EU, and encompasses a wide range of critical areas such as commercial analytics, managed market analytics, diseases analytics, intervention programs, sales force excellence, forecasting, valuation, and portfolio analytics. Throughout my illustrious career, I have had the privilege of working closely with influential decision-makers and forging strategic alliances with renowned organizations such as GlaxoSmithKline, BMS, Amgen, Medtronic, Mallinckrodt, Almirall, BI, GSK, Bayer, and Roche. Additionally, I have engaged with leading medical device companies including Medtronic, J&J, Boston Scientific, and Qiagen, further augmenting my comprehensive understanding of the complexities within the pharma and medical device sectors. Over the course of my professional journey, I have showcased exceptional people management skills, skillfully leading and motivating teams for more than 11 years. Moreover, my prowess in account management has been honed for a decade, establishing me as an invaluable partner for clients. My strengths lie in my profound knowledge of clinical operations, advanced analytics, business/market dynamics, and cutting-edge technology solutions. This expertise enables me to construct robust frameworks for delivering strategic recommendations and spearheading the development of groundbreaking products and services. I possess a deep understanding of Forecasting, RWE, HEOR, Market assessment, Brand Insight, New drug launches, Digital, KOL/DOL targeting strategy, and SFE, Specialty/PBM analytics.
